Recruitment unclearEUCTR 2008-000370-20
Official study titleEvaluation of pharmacokinetic and pharmacodynamic interactions between escitalopram and drugs used for the treatment of bipolar disorders.
Original registry wording; source language not specified.
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In ItalyBipolarityHistorical research record
- Countries
- Italy
- Sponsor
- AZIENDA OSPEDALIERA PISANA
CompletedNCT01909011
Official study titleA Single Blind, Randomized, Sham Controlled Study of Cranial Electrical Stimulation in Bipolar II Disorder
This study has finished and is no longer accepting participants.
In New YorkBipolarityDevice studyAges 18–85
- Countries
- United States
- Sponsor
- Beth Israel Medical Center
CompletedNCT00745966
Official study titleA 8-Week, Multicenter, Open-Label, Observational Study of Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including Kyunggi-doBipolarityObservational studyAges 18–65
- Countries
- South Korea
- Sponsor
- AstraZeneca
CompletedNCT04222816
Official study titleEffect of Regulated Add -on Sodium Chloride Intake on Stabilization of Serum Lithium Concentration in Bipolar Disorder: A Randomized Controlled Trial
This study has finished and is no longer accepting participants.
In KhordhaBipolarityMedication studyAges 18–60
- Countries
- India
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
CompletedNCT00156325
Official study titleA Double-Blind, Placebo-Controlled Trial of Escitalopram as a Mood Stabilizer for Bipolar II Disorder
This study has finished and is no longer accepting participants.
In SydneyBipolarityMedication studyAges 18–65
- Countries
- Australia
- Sponsor
- The University of New South Wales
TerminatedNCT01674010
What is this study about?This study evaluates the safety and effectiveness of ELND005 for people with bipolarity.
This study ended early.
Multiple locations, including BirminghamBipolarityMedication studyAges 18–65
- Countries
- United States, France, Canada, + 6 others
- Sponsor
- OPKO Health, Inc.
CompletedNCT01188148
Official study titleSeries Studies of Bipolar Disorder-Valproate add-on Memantine Treatment
This study has finished and is no longer accepting participants.
In TainanBipolarityMedication studyAges 18–65
- Countries
- Taiwan
- Sponsor
- National Cheng-Kung University Hospital
TerminatedEUCTR 2004-000687-27
Official study titleA 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder
Original registry wording; source language not specified.
This study ended early.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In AustriaBipolarityHistorical research record
- Countries
- Austria, Czechia, Slovakia
- Sponsor
- Novartis Pharma AG
